October 21, 2015 Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains
October 15, 2015 Kite Pharma Announces Exclusive License with the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat Tumors Expressing MAGE
October 15, 2015 Kite Pharma Receives Positive Opinions for Orphan Drug Designation in the European Union (EU) for KTE-C19 in Three Additional Hematological Indications
October 7, 2015 Kite Pharma Commends Steven A. Rosenberg, M.D., Ph.D., on the Prestigious Medal of Honor Award From the American Cancer Society
October 1, 2015 Kite Pharma Announces Peer-Reviewed Publication of T Cell Receptor Based Product Candidate to Treat HPV-Associated Cancers
September 25, 2015 Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference
September 24, 2015 Arno Therapeutics’ AR-13 Data Show Promise as Potential New Therapeutic Option for Cystic Fibrosis Patients with Serious Bacterial Infections
September 24, 2015 Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs
September 19, 2015 Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs
September 19, 2015 Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Exposition
September 15, 2015 Franz B. Humer, Former Chairman and CEO of Roche Group, Appointed to Kite Pharma’s Board of Directors
September 14, 2015 AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015
September 11, 2015 Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite’s Lead Cancer T-Cell Immunotherapy
September 3, 2015 Kite Pharma Commends Honors Conferred to Scientific Advisory Board Members for Their Significant Contributions to Medicine
August 18, 2015 Arno Therapeutics Receives Authorization to Proceed with Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer
August 14, 2015 Kite Pharma to Hold Conference Call to Provide a Corporate Update on Monday, August 17, 2015
August 6, 2015 Capricor Therapeutics to Hold Second Quarter 2015 Business Update and Financial Results Conference Call on August 13, 2015 at 4:30 p.m. EDT
